USA - NASDAQ:VECT - CH1109007893 - Common Stock
ChartMill assigns a Buy % Consensus number of 48% to VECT. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-23 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-05-23 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2023-05-23 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-04-20 | Piper Sandler | Maintains | Overweight |
| 2022-12-13 | Jefferies | Initiate | Buy |
| 2022-10-13 | SVB Leerink | Maintains | Outperform |
| 2022-07-01 | Piper Sandler | Initiate | Overweight |
| 2021-05-04 | SVB Leerink | Initiate | Outperform |
| 2021-05-04 | Credit Suisse | Initiate | Outperform |
| 2021-05-04 | B of A Securities | Initiate | Buy |
8 analysts have analysed VECT and the average price target is 18.36 USD. This implies a price increase of 8.96% is expected in the next year compared to the current price of 16.85.
The consensus rating for VectivBio Holding AG (VECT) is 47.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering VectivBio Holding AG (VECT) is 8.